A Phase 2/3 interventional study of Somatostatin analog in Pancreatic Diseases, sponsored by Mayo Clinic. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Mayo Clinic · Phase 2/3, Interventional, and Treatment
This phase II/III trial compares the effect octreotide and the duration of antibiotic treatment has on outcomes in patients undergoing a Whipple procedure. A Whipple procedure is a surgery that may remove all or part of the pancreas, part of the intestines, stomach and gallbladder. Leakage from the pancreas due to damaged pancreatic ducts (fistula) is a major complication following pancreatic resection often delaying further treatment and increasing hospital stays. Antibiotics along with octreotide, which works by inhibiting pancreatic secretions, is standard treatment for a pancreatic fistula. This study will determine if the length of antibiotic treatment decreases the rate of fistulas and shortens hospital stays.
169 studies on the registry are indexed under Pancreatic Diseases; 62 are open to participants now.
This study's enrollment of 103 is close to the median of 102 across 84 interventional studies indexed under Pancreatic Diseases.
Browse Pancreatic Diseases studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Active somatostatin analogue combined with perioperative antibiotics
Drug: Somatostatin analog
Placebo combined with perioperative antibiotics
Drug: Somatostatin analog
Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
Also known as: Arm A
Length of Hospital Stay
Assessed by the length of hospital stay (days) following pancreatic surgery.
Time frame: Up to 90 days
Incidence of pancreatic fistula
defined as postoperative drain output of fluid with amylase content more than 3 times the maximum normal serum value and exceeding 10 mL/24 h for more than 3 days
Time frame: Up to 90 days
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is suspended, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic